X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
adult (18) 18
female (18) 18
male (18) 18
hiv infections - drug therapy (17) 17
treatment outcome (17) 17
index medicus (16) 16
middle aged (16) 16
raltegravir potassium (12) 12
drug therapy, combination (10) 10
viral load (10) 10
cd4 lymphocyte count (9) 9
double-blind method (9) 9
safety (9) 9
aged (8) 8
anti-hiv agents - therapeutic use (8) 8
drug therapy (8) 8
human immunodeficiency virus--hiv (8) 8
medicine, general & internal (8) 8
raltegravir (8) 8
abridged index medicus (7) 7
clinical trials (7) 7
hiv infection (7) 7
hiv infections - virology (7) 7
hiv-1 - drug effects (7) 7
hiv-1 - isolation & purification (7) 7
infectious diseases (7) 7
rna, viral - blood (7) 7
antiretroviral drugs (6) 6
drug administration schedule (6) 6
efficacy (6) 6
hiv integrase inhibitors - therapeutic use (6) 6
hiv-1 (6) 6
pyrrolidinones - therapeutic use (6) 6
anti-hiv agents - adverse effects (5) 5
antiviral agents (5) 5
care and treatment (5) 5
combination therapy (5) 5
dosage and administration (5) 5
health aspects (5) 5
hiv-1 - genetics (5) 5
immunology (5) 5
infection (5) 5
integrase inhibitor raltegravir (5) 5
internal medicine (5) 5
prevalence (5) 5
protease inhibitors (5) 5
adolescent (4) 4
antiretroviral therapy (4) 4
hiv integrase inhibitors - administration & dosage (4) 4
integrase inhibitor (4) 4
organic chemicals - therapeutic use (4) 4
plasma (4) 4
pyrrolidinones (4) 4
pyrrolidinones - administration & dosage (4) 4
pyrrolidinones - adverse effects (4) 4
ribavirin (4) 4
tenofovir (4) 4
2008 recommendations (3) 3
adenine - analogs & derivatives (3) 3
adenine - therapeutic use (3) 3
aids/hiv (3) 3
analysis (3) 3
antiretroviral drug-resistance (3) 3
article (3) 3
benzoxazines - therapeutic use (3) 3
dose-response relationship, drug (3) 3
drug resistance (3) 3
drug resistance, viral (3) 3
drugs (3) 3
efavirenz (3) 3
emtricitabine (3) 3
evaluation (3) 3
hepatitis (3) 3
hepatitis c, chronic - complications (3) 3
hepatitis c, chronic - drug therapy (3) 3
hiv (3) 3
hiv infections - immunology (3) 3
hiv integrase inhibitors - adverse effects (3) 3
hiv patients (3) 3
hiv-1 - physiology (3) 3
infectious disease (3) 3
optimized background therapy (3) 3
organic chemicals - adverse effects (3) 3
organophosphonates - therapeutic use (3) 3
research (3) 3
society-usa panel (3) 3
studies (3) 3
treatment-experienced patients (3) 3
treatment-naive patients (3) 3
united states (3) 3
virology (3) 3
acquired immune deficiency syndrome--aids (2) 2
aids (2) 2
anti-hiv agents - administration & dosage (2) 2
anti-retroviral agents - administration & dosage (2) 2
australia (2) 2
benzofurans - administration & dosage (2) 2
benzofurans - therapeutic use (2) 2
cd4 antigen (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10003, pp. 1537 - 1545
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9692, pp. 796 - 806
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 396 - 407
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2015, Volume 2, Issue 8, pp. e319 - e327
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 587 - 596
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 12, pp. 907 - 915
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9569, pp. 1261 - 1269
Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANTIRETROVIRAL DRUGS | THERAPY | HIV-1-INFECTED INDIVIDUALS | INFECTION | DRUG-RESISTANCE | PREVALENCE | ENFUVIRTIDE | HIV-1 | Drug Resistance, Multiple | Humans | Middle Aged | Male | HIV Integrase Inhibitors - administration & dosage | Viral Load | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | Atazanavir Sulfate | Adult | Female | Raltegravir Potassium | Organic Chemicals - administration & dosage | Pyridines - therapeutic use | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Logistic Models | Treatment Outcome | Pyrrolidinones | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Pyridines - pharmacology | Oligopeptides - pharmacology | Viral drug resistance | Care and treatment | Dosage and administration | Drug therapy | HIV infection | Raltegravir | Design | Studies | Antiretroviral drugs | Plasma | Inhibitor drugs | Protease inhibitors | Conferences | Human immunodeficiency virus--HIV | Mortality | Gene expression | Drug resistance | Patients | RNA-directed DNA polymerase | Laboratories | Toxicity | Viruses | Genomes | Randomization | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Safety | Drug dosages | Integrase | Phenotypes | Effectiveness | Proteinase inhibitors | Ribonucleic acid--RNA | Antiretroviral therapy | CD4 antigen | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Nucleosides | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2010, Volume 55, Issue 1, pp. 39 - 48
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 339 - 354
Journal Article